BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with H. Lundbeck A/S for use of [F-18]MK-6240, an investigational imaging agent to be used in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease.
The collaboration is focused on using [F-18]MK-6240 as a biomarker in Lundbeck neurodegenerative disease research studies. The parties will collaborate to evaluate ways to diagnose, prevent and evaluate new treatments for neurodegenerative diseases in humans.
“At Cerveau we are focused on enhancing access to key technologies that we believe have the potential to advance human health,” says Rick Hiatt, chief executive officer, Cerveau Technologies, Inc.. “We are excited by the opportunity to work with Lundbeck with the goal of expanding the availability of this novel investigational imaging agent to the broader scientific community.”
“There is a critical need for sensitive biomarkers to guide clinical development of new treatments for neurodegenerative diseases” says Mads Dalsgaard, Vice President of Clinical Development for H. Lundbeck A/S. “This collaboration with Cerveau is a great example of working together in a precompetitive fashion to accelerate the development of better therapies for patients with neurodegenerative disease such as Alzheimer’s.”
About Cerveau Technologies, Inc.
Cerveau Technologies, Inc. is a partnership between Enigma Biomedical Group, Inc. and Sinotau Pharmaceutical Group. Cerveau’s vision is globally develop diagnostics and technology that positively impact patients with neurodegenerative disorders including Alzheimer’s disease.
About H. Lundbeck A/S
H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson's disease and Alzheimer's disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders — we call this Progress in Mind.
Read more at www.lundbeck.com/global/about-us/progress-in-mind.
Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have research centres in China and Denmark and production facilities in China, Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.3 billion).
For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.